title: Prevention of mother-to-child transmission of HIV in developing countries: recommendations for practice. The Ghent International Working Group on Mother-To-Child Transmission of HIV.
abstract: OBJECTIVE
  Different approaches to prevent mother-to-child transmission of HIV are being evaluated in developing countries. The first trials using a short regimen of zidovudine have been successful in Thailand, Côte d'Ivoire and Burkina Faso. International and local strategies are now being considered. The Ghent International Working Group on Mother-to-Child Transmission of HIV developed public health policy options to integrate these interventions into basic and maternal and child health (MCH) services.
  
  
  METHODS
  The following tasks were undertaken: a critical review of randomized trials; an international pooled analysis of late postnatal transmission of HIV through breastfeeding; a review of the cost-effectiveness and cost-benefit of antiretroviral prophylaxis; a feasibility assessment of preventive strategies, including a postal survey on HIV voluntary counselling and testing (VCT) of pregnant women; the identification of requirements and research priorities for prenatal, obstetric and paediatric care. These projects provided the background for a three-day workshop in Ghent, Belgium, in November 1997. Conclusions were further refined, based on 1998 research findings.
  
  
  RESULTS
  A summary of relevant evidence and ten public health recommendations are reported. VCT for pregnant women, a short regimen of zidovudine together with alternatives to breastfeeding currently represent the best option to reduce vertical transmission in most developing countries. The primary goal of the integrated package supporting these interventions is to alleviate overall maternal and infant morbidity and mortality.
  
  
  CONCLUSIONS
  Prevention of mother-to-child transmission of HIV should now be considered for integration into basic health and MCH services of selected countries, with the involvement of governments and donor agencies.
authors.affiliation: Unité INSERM No. 330, Université Victor Segalen Bordeaux 2, France. Francois.dabis@dim.u-bordeaux2.fr
authors.forename: F
authors.initials: F
authors.lastname: Dabis
authors.forename: M L
authors.initials: ML
authors.lastname: Newell
authors.forename: L
authors.initials: L
authors.lastname: Fransen
authors.forename: J
authors.initials: J
authors.lastname: Saba
authors.forename: P
authors.initials: P
authors.lastname: Lepage
authors.forename: V
authors.initials: V
authors.lastname: Leroy
authors.forename: M
authors.initials: M
authors.lastname: Cartoux
authors.forename: N
authors.initials: N
authors.lastname: Meda
authors.forename: D K
authors.initials: DK
authors.lastname: Whynes
authors.forename: C
authors.initials: C
authors.lastname: Peckham
authors.forename: R
authors.initials: R
authors.lastname: Nduati
authors.forename: P
authors.initials: P
authors.lastname: Msellati
authors.forename: I D
authors.initials: ID
authors.lastname: Vincenzi
authors.forename: P
authors.initials: P
authors.lastname: van de Perre
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D001942:Breast Feeding; D003376:Counseling; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission*; D006801:Humans; D007223:Infant; D007224:Infant Care; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D011295:Prenatal Care; D016032:Randomized Controlled Trials as Topic; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine